MELIOR PHARMACEUTICALS
Many blockbuster drugs were only serendipitously discovered to be efficacious in the indications for which they were ultimately marketed. For example, Viagra® ($2 billion annual sales), Gemzar® ($1.2 billion annual sales), Evista® ($1.0 billion annual sales) and Propecia® are all examples of drugs that were originally developed for use in one indication but, by chance, were discovered to be effective for a very different one.
MELIOR PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Exton, Pennsylvania, United States
Country:
United States
Website Url:
http://www.meliorpharmaceuticals.com
Total Employee:
1+
Status:
Active
Contact:
(610) 280-0633
Email Addresses:
[email protected]
Total Funding:
375 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Google Tag Manager Google Universal Analytics Global Site Tag Typekit EmailMeForm
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.meliorpharmaceuticals.com Semrush global rank: 5.85 M Semrush visits lastest month: 1.42 K
- Host name: vux.netsolhost.com
- IP address: 206.188.193.17
- Location: Jacksonville United States
- Latitude: 30.1426
- Longitude: -81.5727
- Metro Code: 561
- Timezone: America/New_York
- Postal: 32258
More informations about "Melior Pharmaceuticals"
Melior Pharmaceuticals | Biopharmaceutical Research …
Melior Pharmaceuticals is a mid-stage biopharmaceutical company developing a pipeline of innovative, de-risked drug candidates in disease areas with significant unmet needs.See details»
Management Team - Melior Pharmaceuticals
Meet the management team of Melior Pharmaceuticals, responsible for business development and investment inquiries.See details»
Melior Pharmaceuticals - Crunchbase Company Profile & Funding
Melior Pharmaceuticals is a clinical stage pharmaceutical company developing treatment for metabolic disease and skin disorders. Many blockbuster drugs were only serendipitously …See details»
Technology Melior Pharmaceuticals | Melior Affiliate
Melior Pharmaceuticals leverages the proprietary technology if its affiliate company, Melior Discovery, to identify new indications for drugs that have existing clinical data in other …See details»
Melior Pharmaceuticals I, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Melior Pharmaceuticals I, Inc. of Exton, PA. Get the latest business insights from Dun & Bradstreet.See details»
Melior Pharmaceuticals - VentureRadar
Website: http://meliorpharmaceuticals.com/ Develops a diverse pipeline of mid-stage biopharmaceutical drug candidates targeting Type 2 Diabetes, Nonalcoholic Steatohepatitis, …See details»
Adhera Therapeutics Expands Relationship with Melior
Oct 20, 2021 · Melior Discovery and its companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique …See details»
Melior Pharmaceuticals - Overview, News & Similar companies
View Melior Pharmaceuticals (www.meliorpharmaceuticals.com) location in Pennsylvania, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Melior Pharmaceuticals, Exton, PA, US | Company Information
Interested in this type of business for your B2B prospection? Buy up to 164,480 business data concerning 110,314 similar businesses for 11031.4 €!See details»
Melior Pharmaceuticals, Inc. | Insights
Jun 10, 2021 · Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Melior Pharmaceuticals Announces Entry Into “Letter …
Jun 7, 2021 · EXTON, Pa.-- ( BUSINESS WIRE )--Melior Pharmaceuticals (Melior) announced that it has signed a “letter of intent” with Adhera Therapeutics, Inc . (OTCPK: ATRX; Adhera) for the acquisition of...See details»
Melior Pharmaceuticals - Products, Competitors, Financials, …
Melior Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing innovative therapies for diseases with significant unmet needs. The company's main offerings …See details»
Mesocarb - Melior Pharmaceuticals
Melior Pharmaceuticals is a mid-staged biopharmaceutical company developing a pipeline of de-risked, molecules in therapeutic areas of significant unmet need.See details»
Melior Is Selected as a Top 20 CRO by Pharma Tech Outlook
Jun 22, 2023 · Melior Discovery and its sister companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the …See details»
Melior Pharmaceuticals I, Inc. (Melior Pharmaceuticals I, Inc.) - 药物 …
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in …See details»
Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary ...
Sep 15, 2020 · EXTON, Pa.-- ( BUSINESS WIRE )--Melior Pharmaceuticals (Melior) has been awarded a grant from the Commonwealth of Pennsylvania’s COVID-19 Vaccines, Treatments …See details»
Adhera Therapeutics Expands Relationship with Melior …
Oct 20, 2021 · As disclosed on August 24, 2021, Adhera executed an exclusive license agreement with Melior Pharma 1 granting Adhera sole rights to develop MLR-1023 as a novel …See details»
Melior Pharmaceuticals Receives IND Clearance from US FDA for …
Mar 9, 2021 · EXTON, Pa.-- ( BUSINESS WIRE )--Melior Pharmaceuticals (Melior) announced that it has received clearance of its Investigational New Drug (IND) application for the clinical …See details»
Adhera Signs Definitive License Agreement with Melior
Jul 29, 2021 · Adhera believes that leveraging decades of safety data and previous work conducted by Melior Discovery (“Melior”), an in vivo pharmacology-focused biopharmaceutical …See details»
Melior Pharmaceuticals Announces Positive Results in Phase 2B …
May 14, 2019 · EXTON, Pa.-- ( BUSINESS WIRE )--Melior Pharmaceuticals I, Inc (Melior) announced today that its novel first-in-class insulin sensitizer, tolimidone, has demonstrated …See details»